hotspot -WSS

hotspot

author：leisure time 2025-09-05 11:31:50 - browse：853

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： FDA moves to stop vape shops from selling Elf Bar, Esco Bars

hotspot

WSS

The best solution to the drug shortages problem

Methadone doses haven’t kept up in the age of fentanyl

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Sanders adds drug shortage policies to pandemic preparedness bill

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

focus

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

How dance can help nurses traumatized by Covid

The high cost of giving birth even with insurance

Startup Neumora takes a novel depression drug to Phase 3

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The best solution to the drug shortages problem

Sports medicine is finally prioritizing gender equality

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Anavex keeps shifting the goalposts in its clinical trials

entertainment

Emergent cuts jobs, executive role in business shake

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Listen: Wegovy in the brain & pivotal Alzheimer's data

Group opposing PBM reform sets lobbying record

Wegovy’s successful heart trial raises vital question about weight loss

AI can’t replace a physician’s gut feeling

focus

hotspot

hotspot

focus